Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment
暂无分享,去创建一个
K. Ohkawa | K. Ikezawa | S. Nagata | R. Takada | Yugo Kai | M. Urabe | Hirofumi Akita
[1] Naomi Uchiyama,et al. Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary–pancreatic cancers , 2023, Journal of Gastroenterology.
[2] M. Hogg,et al. Adult Pancreatoblastoma: a Rare Pancreatic Tumor. , 2023, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.
[3] Tsutomu Sato,et al. A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX , 2023, Surgical Case Reports.
[4] M. Ladanyi,et al. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] N. Sasahira,et al. Outcomes of lung oligometastasis in pancreatic cancer. , 2023, Japanese journal of clinical oncology.
[6] M. Bali,et al. Rare Solid Pancreatic Lesions on Cross-Sectional Imaging , 2023, Diagnostics.
[7] Dakeun Lee,et al. Simultaneous establishment of pancreatic cancer organoid and cancer‐associated fibroblast using a single‐pass endoscopic ultrasound‐guided fine‐needle biopsy specimen , 2023, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.
[8] D. Jain,et al. Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma , 2023, Diagnostic cytopathology.
[9] I. Tirosh,et al. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting , 2023, Cancer discovery.
[10] P. Kornprat,et al. Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients. , 2023, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[11] Rachel B. Keller,et al. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness , 2023, JCO precision oncology.
[12] K. Takaori,et al. Mixed acinar-neuroendocrine carcinoma of the pancreas with positive for microsatellite instability: a case report and review of the literature , 2023, Surgical Case Reports.
[13] G. Sauter,et al. CELA3B immunostaining is a highly specific marker for acinar cell carcinoma of the pancreas , 2023, PloS one.
[14] K. Takami,et al. Outcomes of surgical resection for pulmonary metastasis from pancreatic cancer , 2023, Surgery Today.
[15] W. Korn,et al. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC)Unveils New Actionable Genomic Aberrations in PACC. , 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] R. Schulick,et al. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. , 2023, Surgery.
[17] Y. Matsuno,et al. Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers , 2023, Cancer science.
[18] G. Mazzarella,et al. Solid pseudopapillary tumor of the pancreas: A systematic review of clinical, surgical and oncological characteristics of 1384 patients underwent pancreatic surgery. , 2023, Hepatobiliary & pancreatic diseases international : HBPD INT.
[19] H. Seno,et al. A case of unresectable ectopic acinar cell carcinoma developed in the portal vein in complete response to FOLFIRINOX therapy , 2023, Clinical Journal of Gastroenterology.
[20] M. Moriguchi,et al. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan , 2023, Journal of Gastroenterology.
[21] R. Yamada,et al. Pancreatic Mixed Acinar-neuroendocrine-ductal Carcinoma: A Case Report and Literature Review , 2023, Internal medicine.
[22] R. Pommier,et al. Referral and treatment patterns in pancreatic acinar cell carcinoma: A regional population-level analysis. , 2023, American journal of surgery.
[23] M. Budzik,et al. Rare Non-Neuroendocrine Pancreatic Tumours , 2023, Cancers.
[24] G. Prager,et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. , 2023, European journal of cancer.
[25] T. Okusaka,et al. Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile , 2023, Diagnostics.
[26] P. Philip,et al. Neoadjuvant therapy for pancreatic cancer , 2023, Nature Reviews Clinical Oncology.
[27] T. Ohtsuka,et al. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis , 2023, International Journal of Clinical Oncology.
[28] Yang Zhang,et al. Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma? , 2023, Journal of cancer metastasis and treatment.
[29] N. Hiraoka,et al. Novel Insights Into Immunohistochemical Analysis For Acinar Cell Neoplasm of The Pancreas , 2023, The American journal of surgical pathology.
[30] N. Sugimoto,et al. Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice , 2023, Cancers.
[31] G. Gores,et al. Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States , 2023, Cancers.
[32] E. Chiorean,et al. The role of molecular testing in pancreatic cancer , 2023, Therapeutic advances in gastroenterology.
[33] J. Neoptolemos,et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. , 2022, The lancet. Gastroenterology & hepatology.
[34] H. Trottier,et al. Endoscopic Ultrasound Guided Fine Needle Aspiration versus Endoscopic Ultrasound Guided Fine Needle Biopsy for Pancreatic Cancer Diagnosis: A Systematic Review and Meta-Analysis , 2022, Diagnostics.
[35] M. Fukayama,et al. Derivation of pancreatic acinar cell carcinoma cell line HS‐1 as a patient‐derived tumor organoid , 2022, Cancer science.
[36] Dheeraj R. Gopireddy,et al. Pancreatic acinar cell carcinoma: A comprehensive review , 2022, World journal of gastroenterology.
[37] Yu Liu,et al. Differentiation between solid pseudopapillary tumor and acinar cell carcinoma of the pancreas based on computed-tomography features. , 2022, Asian journal of surgery.
[38] K. Nagai,et al. Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a Germline BRCA2 Variant. , 2022, Pancreas.
[39] T. Okusaka,et al. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry , 2022, Journal of Gastroenterology.
[40] S. Yagi,et al. Pancreatic acinar cell carcinoma projected from the ampulla of Vater with extensive intraductal tumour growth. , 2022, The American journal of gastroenterology.
[41] S. Yachida,et al. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. , 2022, Japanese journal of clinical oncology.
[42] Joon-Oh Park,et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] M. Unno,et al. Pancreatic mixed acinar–neuroendocrine carcinoma in a patient with a germline BRCA2 mutation: a case report , 2022, Clinical Journal of Gastroenterology.
[44] K. Deng,et al. Imaging and Clinicopathological Features of Acinar Cell Carcinoma , 2022, Frontiers in Oncology.
[45] Shota Yamamoto,et al. Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report , 2022, Cancer reports.
[46] E. Sokol,et al. The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. , 2022, Journal of the National Cancer Institute.
[47] R. Ashida,et al. Endoscopic ultrasound‐guided tissue acquisition for pancreatic ductal adenocarcinoma in the era of precision medicine , 2022, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.
[48] N. Sasahira,et al. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study , 2022, Annals of Surgical Oncology.
[49] S. Yamada,et al. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01) , 2022, Annals of surgery.
[50] M. Papotti,et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms , 2022, Endocrine Pathology.
[51] Kazuhiro Yoshida,et al. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis , 2022, Journal of hepato-biliary-pancreatic sciences.
[52] M. Takenaka,et al. Comparison of 22G Standard and Franseen Needles in Endoscopic Ultrasound-Guided Tissue Acquisition for Diagnosing Solid Pancreatic Lesions: A Multicenter Randomized Controlled Trial. , 2022, Gastrointestinal endoscopy.
[53] R. Higuchi,et al. A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis , 2022, Clinical Journal of Gastroenterology.
[54] S. Maithel,et al. Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma , 2022, Journal of surgical oncology.
[55] K. Ohkawa,et al. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer , 2022, Endoscopy International Open.
[56] D. Melisi,et al. Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion , 2022, JCO precision oncology.
[57] T. Keck,et al. Survival Outcome and Prognostic Factors for Pancreatic Acinar Cell Carcinoma: Retrospective Analysis from the German Cancer Registry Group , 2021, Cancers.
[58] Jin‐Young Jang,et al. Clinical Characteristics of Resected Acinar Cell Carcinoma of the Pancreas: A Korean Multi-Institutional Study , 2021, Cancers.
[59] T. Teshima,et al. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer , 2021, Cancers.
[60] A. Omiyale. Adult pancreatoblastoma: Current concepts in pathology , 2021, World journal of gastroenterology.
[61] G. Sauter,et al. Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas , 2021, The American journal of surgical pathology.
[62] A. Biankin,et al. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] H. Imaoka,et al. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis , 2021, Diagnostics.
[64] C. Weldon,et al. Pancreatoblastoma in children: EXPeRT/PARTNER diagnostic and therapeutic recommendations , 2021, Pediatric blood & cancer.
[65] K. Ohkawa,et al. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer , 2021, JGH open : an open access journal of gastroenterology and hepatology.
[66] Jeffrey W. Clark,et al. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[67] K. Nathanson,et al. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] A. Nakano,et al. Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study , 2021, BMC Surgery.
[69] Zhengjia Chen,et al. Survival Outcomes of Acinar Cell Pancreatic Cancer , 2021, Pancreas.
[70] M. Unno,et al. Acinar Cell Carcinoma with Morphological Change in One Month , 2021, Internal medicine.
[71] D. Jäger,et al. Metastatic Acinar Cell Carcinoma of the Pancreas , 2021, Pancreas.
[72] Ling Zhang,et al. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma. , 2021, Surgical oncology.
[73] Fenghua Wang,et al. Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature , 2021, Clinical Medicine Insights. Oncology.
[74] R. Berger,et al. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. , 2021, Gastroenterology.
[75] E. Petricoin,et al. Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[76] D. Cao,et al. Efficacy of chemotherapy combined with toripalimab in PD-L1–positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report , 2020, Tumori.
[77] M. Li,et al. The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: A population-based study , 2020, PloS one.
[78] H. Friess,et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. , 2020, The lancet. Gastroenterology & hepatology.
[79] J. Furuse,et al. Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma , 2020, Pancreas.
[80] E. Stelow,et al. The cytologic and immunohistochemical findings of pancreatic mixed acinar‐endocrine carcinoma , 2020, Diagnostic cytopathology.
[81] W. Lou,et al. Clinical Analysis of Acinar Cell Carcinoma of the Pancreas: A Single-Center Experience of 45 Consecutive Cases , 2020, Cancer control : journal of the Moffitt Cancer Center.
[82] S. Fröhling,et al. Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma , 2020, Cold Spring Harbor molecular case studies.
[83] P. Kurtin,et al. CPA1 and REG1a as New Markers for Pancreatic Acinar Cell Carcinoma. , 2020, Human Pathology.
[84] S. Ramkissoon,et al. Pediatric BRAF (V600E)-Mutated Pancreatic Acinar Cell Carcinoma With Complete and Durable Response to Dabrafenib and Trametinib. , 2020, JCO precision oncology.
[85] Y. Kimura,et al. Rare case of acinar cell carcinoma with multiple lesions in the pancreas , 2020, JGH open : an open access journal of gastroenterology and hepatology.
[86] T. Fishbein,et al. Robot-assisted combined pancreatectomy/hepatectomy for metastatic pancreatic acinar cell carcinoma: case report and review of the literature , 2020, Clinical Journal of Gastroenterology.
[87] L. Shen,et al. Patients With Acinar Cell Carcinoma of the Pancreas After 2005 , 2020, Pancreas.
[88] N. Ohike,et al. A case of pancreatic mixed acinar–neuroendocrine carcinoma successfully diagnosed with endoscopic ultrasound-guided fine needle aspiration , 2020, Clinical Journal of Gastroenterology.
[89] N. Schultz,et al. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection , 2020, Clinical Cancer Research.
[90] R. Hruban,et al. Acinar cell carcinoma of the pancreas: a clinicopathologic and cytomorphologic review. , 2020, Journal of the American Society of Cytopathology.
[91] G. Lahat,et al. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer , 2020, Annals of Surgical Oncology.
[92] E. Petricoin,et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. , 2020, The Lancet. Oncology.
[93] P. Kuo,et al. Clinically resectable acinar cell carcinoma of the pancreas: Is there a benefit to adjuvant systemic therapy? , 2020, American journal of surgery.
[94] D. Park,et al. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours. , 2020, Pathology.
[95] F. Motoi,et al. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. , 2020, Japanese journal of clinical oncology.
[96] A. Chen,et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] L. Wood,et al. Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features. , 2019, Archives of pathology & laboratory medicine.
[98] S. Katagiri,et al. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. , 2019, Japanese journal of clinical oncology.
[99] Kat S. Moore,et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening , 2019, Proceedings of the National Academy of Sciences.
[100] Joon-Oh Park,et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.
[101] K. Landa,et al. Underutilization of surgical resection in patients with pancreatic acinar cell carcinoma. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[102] I. Nagtegaal,et al. Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review , 2019, Cancer biology & therapy.
[103] Thierry Lecomte,et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.
[104] D. Cao,et al. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib , 2018, Medicine.
[105] Sheng-ping Li,et al. Nomogram to Predict Cancer-Specific Survival in Patients with Pancreatic Acinar Cell Carcinoma: A Competing Risk Analysis , 2018, Journal of Cancer.
[106] S. Cingarlini,et al. Imaging presentation of pancreatic neuroendocrine neoplasms , 2018, Insights into Imaging.
[107] Robert E Denroche,et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. , 2018, Cancer discovery.
[108] E. Fishman,et al. Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance , 2018, Abdominal Radiology.
[109] D. V. Von Hoff,et al. Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors , 2017, World journal of gastroenterology.
[110] H. Ohira,et al. Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma , 2017, Clinical Journal of Gastroenterology.
[111] M. Matsuda,et al. Pancreatic acinar cell carcinoma with extensive tumor embolism at the trunk of portal vein and pancreatic intraductal infiltration , 2017, Clinical Journal of Gastroenterology.
[112] M. Omata,et al. Genetic basis of a common tumor origin in the development of pancreatic mixed acinar-neuroendocrine-ductal carcinoma: A case report , 2017, Oncology letters.
[113] D. Tuveson,et al. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. , 2017, Gastrointestinal endoscopy.
[114] Tae Won Kim,et al. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen , 2016, Cancer research and treatment : official journal of Korean Cancer Association.
[115] D. Coppola,et al. Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas. , 2016, Cancer control : journal of the Moffitt Cancer Center.
[116] J. Werner,et al. Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma , 2016, Journal of Cancer Research and Clinical Oncology.
[117] S. Muthuswamy. Abstract PR01: Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids , 2016 .
[118] N. Sata,et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.
[119] Sinan Wang,et al. Acinar cell carcinoma: a report of 19 cases with a brief review of the literature , 2016, World Journal of Surgical Oncology.
[120] C. Yeo,et al. Neoadjuvant Chemotherapy and Appleby Procedure for Pancreatic Acinar Cell Carcinoma: A Case Report , 2016, Case reports in pancreatic cancer.
[121] Jun Dong,et al. Clinical features and CT/MRI findings of pancreatic acinar cell carcinoma. , 2015, International journal of clinical and experimental medicine.
[122] F. Sessa,et al. Acinar Cell Carcinoma of the Pancreas: Overview of Clinicopathologic Features and Insights into the Molecular Pathology , 2015, Front. Med..
[123] Masakazu Yamamoto,et al. Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas , 2015, Scientific Reports.
[124] M. Spector,et al. Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.
[125] R. Gershoni-baruch,et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.
[126] J. Herman,et al. Whole‐exome sequencing of pancreatic neoplasms with acinar differentiation , 2014, The Journal of pathology.
[127] P. Bhosale,et al. CT imaging features of acinar cell carcinoma and its hepatic metastases , 2013, Abdominal Imaging.
[128] R. Hruban,et al. Acinar Cell Carcinoma of the Pancreas: Clinical and Cytomorphologic Characteristics , 2013, Korean journal of pathology.
[129] Y. Yatabe,et al. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens , 2013, Pathology international.
[130] J. Cameron,et al. Acinar cell carcinoma of the pancreas: computed tomography features—a study of 15 patients , 2013, Abdominal Imaging.
[131] A. Vanoli,et al. Clinicopathologic Study of 62 Acinar Cell Carcinomas of the Pancreas: Insights Into the Morphology and Immunophenotype and Search for Prognostic Markers , 2012, The American journal of surgical pathology.
[132] H. Imamura,et al. Acinar cell carcinoma of the pancreas: a possible role of S-1 as chemotherapy for acinar cell carcinoma. A case report. , 2012, JOP : Journal of the pancreas.
[133] M. Lowery,et al. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. , 2011, The oncologist.
[134] M. Büchler,et al. Acinar cell carcinoma of the pancreas: is resection justified even in limited metastatic disease? , 2011, American journal of surgery.
[135] J. Tseng,et al. CT and MRI features of acinar cell carcinoma of the pancreas with pathological correlations. , 2010, Clinical radiology.
[136] Cynthia S. Johnson,et al. Pancreatic Acinar Cell Carcinoma: A Multi-institutional Study , 2009, Journal of Gastrointestinal Surgery.
[137] K. Lillemoe,et al. Acinar Cell Carcinoma of the Pancreas in the United States: Prognostic Factors and Comparison to Ductal Adenocarcinoma , 2008, Journal of Gastrointestinal Surgery.
[138] W. Nealon,et al. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. , 2008, Surgery.
[139] Masao Tanaka,et al. Acinar Cell Carcinoma of the Pancreas: Clinical Analysis of 115 Patients From Pancreatic Cancer Registry of Japan Pancreas Society , 2007, Pancreas.
[140] O. Basturk,et al. Intraductal and Papillary Variants of Acinar Cell Carcinomas: A New Addition to the Challenging Differential Diagnosis of Intraductal Neoplasms , 2007, The American journal of surgical pathology.
[141] D. Klimstra. Nonductal neoplasms of the pancreas , 2007, Modern Pathology.
[142] S. Silverman,et al. CT and MRI features of pure acinar cell carcinoma of the pancreas in adults. , 2005, AJR. American journal of roentgenology.
[143] F. Motoi,et al. Pancreatic Cancer Registry in Japan: 20 Years of Experience , 2004, Pancreas.
[144] Cheng‐Yen Chang,et al. Acinar Cell Carcinoma of the Pancreas: Clinical and Computed Tomography Manifestations , 2004, Journal of computer assisted tomography.
[145] Jong Hoon Kim,et al. Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases. , 2003, Pancreas.
[146] M. Gonen,et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] C. Compton,et al. Prevalence and Prognostic Significance of Acinar Cell Differentiation in Pancreatic Endocrine Tumors , 2002, The American journal of surgical pathology.
[148] S. D. Lee,et al. Concurrent chemoradiation is effective in the treatment of alpha-fetoprotein-producing acinar cell carcinoma of the pancreas: report of a case. , 2001, Pancreas.
[149] N. Lemoine,et al. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. , 1993, The American journal of pathology.
[150] D. Klimstra,et al. Acinar Cell Carcinoma of the Pancreas: A Clinicopathologic Study of 28 Cases , 1992, The American journal of surgical pathology.
[151] J. C. Robertson,et al. Syndrome associated with pancreatic acinar cell carcinoma. , 1970, British medical journal.
[152] H. Macmahon,et al. Acinar cell carcinoma of the pancreas with subcutaneous fat necrosis. , 1965, Gastroenterology.
[153] L. Koniaris,et al. Malignant pancreatic tumors: incidence and outcome in 58 pediatric patients. , 2009, Journal of pediatric surgery.
[154] R. Grützmann,et al. World Journal of Surgical Oncology Open Access Curative Resection of a Primarily Unresectable Acinar Cell Carcinoma of the Pancreas after Chemotherapy , 2022 .
[155] M. Kako,et al. World Journal of Gastroenterology , 2022 .